Good Enough for the Top 4%: The Go-to-Market Lesson Every Medtech Startup Needs

MedTech Innovator announced its 2026 accelerator cohort. Congrats if you're one of the lucky few! 65 companies were selected from 1,835 applicants. MTI has a 93% ten-year survival rate among alumni, and $12 billion in follow-on funding raised collectively. By any measure, that's a remarkable track record.

What caught my eye wasn't the selectivity. It was that MTI is committed to go-to-market strategy and value creation as core elements of its curriculum, with particular emphasis on physician adoption, payer considerations, and market access baked into the program from day one.

That emphasis exists for a reason. Most startups treat G2M as something they'll figure out after clearance, and that's usually where things go sideways.

Here's a concrete example of why it matters earlier than some founders think.

Imagine you're building a wireless patient monitor. One of the earliest decisions you'll make, where this device is first used and by whom, sets off a chain of decisions that touches everything downstream.

G2M Decision: 
If the monitor lives in the hospital, you're bundled into existing facility payments, your buyer is a value analysis committee focused on cost per use, and your intended user is a trained clinician in a controlled environment. If it goes home with the patient, you're in remote patient monitoring reimbursement territory, your buyer and revenue model both change, and your intended user is now an untrained patient in an uncontrolled environment.

Regulatory Corollary: 
That single shift triggers a fundamentally different human factors requirement from FDA, a different predicate search, potentially a different device classification, and different evidence of safety and efficacy needed.

Design Corollary: 
The use environment absolutely influences form factor. Many founders who are enamored with their own technology tend to start with the design, pushing its maturity well ahead of regulatory and G2M considerations. The result is considerable rework, or worse, a DOA product.

That's the chain of decisions MTI is trying to get its cohort to think about early. It's the right path, and it applies whether you're one of the 65 chosen companies or not.

Rightley McConnell
VP Client Engagement